Table II.
Features of second line treated patients according to KRAS genotype.
| Overall treated
|
KRAS wild-type
|
KRAS mutant
|
|
|---|---|---|---|
| Total no. (%) | Total no. (%) | Total no. (%) | |
| No. of patients | 40 | 21 (55.3) | 17 (44.7) |
| Sex | |||
| Male/female | 26/14 | 17/4 | 8/9 |
| Age, years | |||
| Median | 65 | 64 | 66 |
| Range | 46-74 | 46-73 | 51-74 |
| ≥65 years | 18 (45) | 9 (43) | 8 (47) |
| Metastatic disease | |||
| Metachronous | 15 (37.5) | 10 (48) | 5 (29) |
| Synchronous | 25 (62.5) | 11 (52) | 12 (71) |
| Primary tumor | |||
| Colon | 18 (45) | 6 (29) | 11 (65) |
| Rectum | 22 (55) | 15 (71) | 6 (35) |
| Sites of metastases | |||
| Liver | 22 (55) | 10 (48) | 11 (65) |
| Lung | 17 (42.5) | 10 (48) | 5 (29) |
| Lymph nodes | 17 (42.5) | 10 (48) | 5 (29) |
| Local | 13 (32.5) | 9 (43) | 4 (23) |
| Other | 12 (30) | 6 (29) | 5 (29) |
| No. of involved sites | |||
| 1 | 16 (40) | 9 (43) | 8 (47) |
| ≥2 | 24 (60) | 12 (57) | 9 (53) |
| Single metastatic sites | |||
| Liver-limited | 9 (22.5) | 3 (14) | 6 (35) |
| Other than liver | 7 (17.5) | 6 (29) | 2 (12) |
| Lung | 4 (10) | 4 (19) | 1 (6) |
| Lymph nodes | 2 (5) | 2 (9) | - |
| Local | - | - | - |
| Other | 1 (2.5) | - | - |
| Multiple metastatic sites | 24 (60) | 12 (57) | 9 (53) |
| Liver metastases | |||
| Single | 3 (7.5) | 1 (5) | 2 (12) |
| Multiple | 20 (50) | 9 (43) | 9 (53) |
| Previous adjuvant chemotherapy | 7 (17.5) | 5 (24) | 1 (6) |
| FA/5-FU bolus | 4 (10) | 3 (14) | - |
| Capecitabine | - | - | - |
| FOLFOX4 | 3 (7.5) | 2 (9) | 1 (6) |
| Previous radiotherapy | 5 (12.5) | 4 (19) | 1 (6) |
| RT alone | 1 (2.5) | 1 (5) | - |
| RT+CT (5-FU continous infusion) | 2 (5) | 2 (9) | - |
| RT+CT (XELOX) | 2 (5) | 1 (5) | 1 (6) |